The requested topic β CB-5083 effects on viral clearance β is not supported by any of the seven supplied claim-level records. None report viral titers, antiviral assays, or infection models. Meta-analysis of that claim is therefore impossible from these sources; proceeding anyway would confabulate. What the records do support is a rigorous critique of CB-5083's cellular toxicity and resistance profile, which is a prerequisite for any clearance-based use case.
In patient-derived iPSC motor neurons (p97 R155H/+), 400 nM CB-5083 for 6 days rescued neuron survival and restored dysregulated proteome levels toward wild-type β but with only 3 biological replicates per group, a single patient line, and one mutation (R155H), limiting generality .
Conversely, sustained CB-5083 pressure in OVSAHO ovarian cancer cells selected resistant populations with 5.3β5.7-fold higher GI50, driven by D1βD2 linker mutations (E470K/E470D) that raise ATPase activity 3.4β5.8-fold and shift inhibitor IC50s (CB-5083 ~3.4β3.8-fold, ML240 ~15-fold, NMS-873 ~2.6β2.9-fold less active) β a resistance mechanism inferred from docking, not co-crystal validation .
Blue = resistance GI50 (cancer cells); red = ATPase activity of E470 mutants (purified protein); grey = IC50 shifts for inhibitor potency. Midpoint values used where ranges (3.4β3.8, 2.6β2.9) were reported.
Acute p97/Ufd1-NPL4 disruption in S phase causes chromatin-bound cohesin (RAD21) accumulation, reduced BrdU incorporation, Ξ³H2AX-driven replication-associated DNA damage β suppressed by aphidicolin and NIPBL depletion. CB-5083 (5 Β΅M, 4 h) reproduced this phenotype, establishing a cell-cycle-specific toxicity pathway that any viral-clearance application in proliferating cells would need to account for .
Confidence: high that the viral-clearance claim is unsupported; moderate that the toxicity/resistance characterization is robust (preclinical, small n, single-cell-line selection in places).
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.